Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16347)	10/12/2003 10:07:56 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Bluegreen > so did I make your day? vbg Now I have to bone up on what I was thinking. vbg I think one of the things I was thinking was how lbp can increase the bactericidal aspect of bpi by up to 10,000 fold. Or was it endotoxin aspect? I forget. I have to research again. Apparently this patent is about non-stimulatory cd14 which we also were talking about. I think the idea of the patent is to tweak bpi (of lbp) for the desired action/effect. I would be very interested if a lbp of (bpi) fusion can have the 10,000 fold synergy of the individual molecules. In any case, it looks like xoma is hot on the case and has been hot on the case and has been silent about it. The gelonin & h65 stuff looks recent but i am not sure yet. Didnt then sell that off years back?